| ESR1 mutations in breast cancer D Dustin, G Gu, SAW Fuqua Cancer 125 (21), 3714-3728, 2019 | 208 | 2019 |
| Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment G Gu, D Dustin, SAW Fuqua Current opinion in pharmacology 31, 97-103, 2016 | 175 | 2016 |
| Designed supramolecular filamentous peptides: balance of nanostructure, cytotoxicity and antimicrobial activity D Xu, L Jiang, A Singh, D Dustin, M Yang, L Liu, R Lund, TJ Sellati, ... Chemical communications 51 (7), 1289-1292, 2014 | 68 | 2014 |
| The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer SM Pejerrey, D Dustin, JA Kim, G Gu, Y Rechoum, SAW Fuqua Hormones and Cancer 9, 215-228, 2018 | 45 | 2018 |
| Filamentous supramolecular peptide–drug conjugates as highly efficient drug delivery vehicles M Yang, D Xu, L Jiang, L Zhang, D Dustin, R Lund, L Liu, H Dong Chemical communications 50 (37), 4827-4830, 2014 | 40 | 2014 |
| Designed filamentous cell penetrating peptides: probing supramolecular structure-dependent membrane activity and transfection efficiency D Xu, D Dustin, L Jiang, DSK Samways, H Dong Chemical communications 51 (59), 11757-11760, 2015 | 35 | 2015 |
| Hormonal modulation of ESR1 mutant metastasis G Gu, L Tian, SK Herzog, Y Rechoum, L Gelsomino, M Gao, L Du, JA Kim, ... Oncogene 40 (5), 997-1011, 2021 | 27 | 2021 |
| Longitudinal monitoring of circulating tumor DNA to predict treatment outcomes in advanced cancers MA Gouda, HJ Huang, SA Piha-Paul, SG Call, DD Karp, S Fu, A Naing, ... JCO Precision Oncology 6, e2100512, 2022 | 18 | 2022 |
| Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate … M Lapin, HJ Huang, S Chagani, M Javle, RT Shroff, S Pant, MA Gouda, ... JCO precision oncology 6, e2100197, 2022 | 15 | 2022 |
| RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer D Dustin, G Gu, AR Beyer, SK Herzog, DG Edwards, H Lin, TL Gonzalez, ... British journal of cancer 124 (1), 191-206, 2021 | 15 | 2021 |
| Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma MA Gouda, J Polivka, HJ Huang, I Treskova, K Pivovarcikova, T Fikrle, ... ESMO open 7 (1), 100357, 2022 | 14 | 2022 |
| Neuroimaging in Alzheimer's disease: preclinical challenges toward clinical efficacy D Dustin, BM Hall, A Annapragada, RG Pautler Translational Research 175, 37-53, 2016 | 11 | 2016 |
| Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis A Aaroe, R Kurzrock, G Goyal, AM Goodman, H Patel, G Ruan, G Ulaner, ... Blood Advances 7 (15), 3984-3992, 2023 | 9 | 2023 |
| The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis G Gu, L Tian, M Gao, Y Rechoum, L Gelsomino, D Dustin, ... Cancer Research 78 (13_Supplement), 22-22, 2018 | 5 | 2018 |
| Abstract S4-02: The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis SAW Fuqua, G Gu, Y Rechoum, L Gelsomino, DJ Dustin, ... Cancer Research 77 (4_Supplement), S4-02-S4-02, 2017 | 2 | 2017 |
| Abstract PS06-06: Analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue-free, multiomic assay in patients with early-stage breast cancer W Janni, T Friedl, B Rack, PA Fasching, A Hartkopf, H Tesch, R Lorenz, ... Cancer Research 84 (9_Supplement), PS06-06-PS06-06, 2024 | | 2024 |
| Evaluating circulating tumor DNA (ctDNA) as a prognostic biomarker utilizing a tissue-free epigenomic assay in early-stage triple negative breast cancer (TNBC) FO Ademuyiwa, CX Ma, K Weilbaecher, R Suresh, L Peterson, R Bose, ... Cancer Research 84 (6_Supplement), 2420-2420, 2024 | | 2024 |
| Hormonal modulation of ESR1 mutant metastasis (vol 40, pg 997, 2021) G Gu, L Tian, SK Herzog, Y Rechoum, L Gelsomino, M Gao, L Du, JA Kim, ... ONCOGENE 41 (3), 460-460, 2022 | | 2022 |
| Abstract PD7-03: Adaptive kinome reprogramming in endocrine therapy resistant metastatic breast cancer D Dustin, G Gu, D Chan, A Beyer, D Edwards, M Ellis, S Fuqua Cancer Research 80 (4_Supplement), PD7-03-PD7-03, 2020 | | 2020 |
| Novel clinical targets revealed by kinome reprogramming in mutant ESR1 metastatic breast cancer D Dustin, G Gu, D Chan, A Beyer, D Edwards, A Corona-Rodriguez, ... Cancer Research 79 (13_Supplement), 921-921, 2019 | | 2019 |
